Back to top

Image: Bigstock

Gol Linhas (GOL) Traffic Declines Year Over Year in September

Read MoreHide Full Article

Thanks to coronavirus-induced weak air-travel demand, Gol Linhas Aereas Inteligentes’ traffic, measured in revenue passenger kilometers, plunged 60.6% year over year in September.

With travel demand falling far below the year-ago levels, the company reduced capacity significantly. In September, capacity measured in available seat kilometers, contracted 60%. With traffic declining more than the amount of capacity contraction, load factor (% of seats filled by passengers) declined 1.3 percentage points year over year. Gol Linhas’ total monthly departures slumped 62.7% and seats tanked 62.9%.

Due to pandemic woes, shares of Gol Linhas have dropped 43.8% since the beginning of March compared with the industry’s 23.5% depreciation.

Despite the unfavorable comparison on a year-over-year basis, domestic air-travel demand has been improving over the past few months. Continuing the trend, domestic demand rose 36% in September from August reading. Supply climbed 35% on a month-over-month basis. Domestic load factor in the month was 80%.

Gol Linhas, which competes with the likes of Azul (AZUL - Free Report) and Copa Holdings (CPA - Free Report) in the Latin American aviation space, operated 270 flights per day on average in September compared with 190 in August. Moreover, the carrier reopened three bases (Juiz de Fora, Londrina and Presidente Prudente) in  September. However, the carrier did not operate regular international flights in the month.

Zacks Rank & Key Pick

Gol Linhas carries a Zacks Rank #3 (Hold), currently.

A better-ranked stock in the broader Transportation sector is Werner Enterprises (WERN - Free Report) , presently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Shares of Werner have gained more than 19% so far this year.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Unique Zacks Analysis of Your Chosen Ticker


Pick one free report - opportunity may be withdrawn at any time


Copa Holdings, S.A. (CPA) - $25 value - yours FREE >>

Werner Enterprises, Inc. (WERN) - $25 value - yours FREE >>

AZUL (AZUL) - $25 value - yours FREE >>

Published in